TransMedics Group (NASDAQ:TMDX) Shares Up 3.7% – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) shares traded up 3.7% during mid-day trading on Tuesday . The stock traded as high as $61.90 and last traded at $61.48. 585,065 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,052,683 shares. The stock had previously closed at $59.28.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. TD Cowen dropped their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 65.76 and a beta of 2.06. The firm has a 50-day simple moving average of $80.40 and a two-hundred day simple moving average of $125.46. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) earnings per share. As a group, analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,459 shares of company stock valued at $1,802,244 over the last ninety days. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its holdings in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares during the last quarter. Harbour Capital Advisors LLC grew its stake in shares of TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares during the last quarter. Signaturefd LLC raised its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Arizona State Retirement System boosted its position in shares of TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after buying an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in shares of TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after purchasing an additional 219 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.